Abstract
Background The Dietary Inflammatory Index (DII), has been specifically designed to capture the inflammatory content of diet and has shown association with neurodegenerative disease related outcomes. But literature is limited on the role of diet-driven inflammation measured by the DII on incident all-cause dementia and Alzheimer’s disease dementia (AD).
Objective We evaluated whether higher DII scores were associated with increased incidence of all-cause dementia and AD over 22.3 years of follow-up in the community-based Framingham Heart Study (FHS) Offspring cohort.
Design, Setting, and Participants Observational longitudinal study in the FHS Offspring cohort. Dementia surveillance for present study: until 2020. Data were analyzed from December 2020 to June 2022. Participants completed a validated 126-item food frequency questionnaires (FFQ), administered at FHS examination cycle 7 (1998-2001) and examination cycle 5 (1991-1995), and/or 6 (1995-1998). Individuals aged <60 years, with prevalent dementia, no dementia follow-up, other relevant neurological diseases, and/or no FFQ data were excluded.
Exposure A DII score (based on the published method by Shivappa et al. 2014) was created based on previous studies linking individual dietary factors to six inflammatory markers (i.e. C-reactive protein, interleukin (IL)-1β, IL-4, IL-6, IL-10, and tumor necrosis factor-alpha), consisting of 36 components. A cumulative DII score was calculated by averaging across a maximum of three FFQs.
Main outcomes and measures Incident all-cause dementia and AD.
Results We included 1487 participants (mean±SD, age in years 69 ± 6; 53·2% women; 31·6% college graduates]). 246 participants developed all-cause dementia (including AD n=187) over a median follow up time of 13·1 years. Higher DII scores were associated with an increased incidence of all-cause dementia and AD following adjustment for age and sex (Hazard ratio (HR) 1·16, 95% confidence interval (CI) 1·07 to 1·25, p<.001; HR 1·16, 95% CI 1·06 to 1·26, p=.001). The relationships remained after additional adjustment for demographic, lifestyle, and clinical covariates (HR 1·21, 95% CI 1·10 to 1·33, p<0.001; HR1·20, 95% CI1·07 to 1·35, p=.001).
Conclusion and relevance Higher DII scores were associated with a higher risk of incident all-cause dementia and AD. Although these promising findings need to be replicated and further validated, our results suggest that diets which correlate with low DII scores may prevent late-life dementia.
Competing Interest Statement
Dr. Melo van Lent is chair of the Alzheimer's Association ISTAART Nutrition Metabolism and Dementia Professional Interest Area; Hannah Gokingco declarations of interest: none; Dr. Meghan I. Short declarations of interest: none; Dr. Mitzi M. Gonzales declarations of interest: holds stock in Abbvie; Dr. Hugo J Aparicio declarations of interest: none; Dr. Joel Salinas has stock in and is Chief Medical Officer of Isaac Health; Dr. Changzheng Yuan declarations of interest: none; Dr. Paul Jacques is part of the Danone North America Essential Dairy and Plant-Based Advisory Board; Dr. Alexa Beiser declarations of interest: none; Dr. Sudha Seshadri declarations of interest: none; Dr. Mini E. Jacob declarations of interest: none; and Dr. Jayandra J. Himali declarations of interest: none.
Funding Statement
The Framingham Heart Study was supported by the National Heart, Lung, and Blood Institute (contract no. N01- HC-25195, HHSN268201500001I and no. 75N92019D00031); and the National Institute on Aging (NIA) (R01 AG054076, R01 AG049607, R01 AG033193, U01 AG049505, U01 AG052409, U01 AG058589, RF1 AG059421)); and by grants from the National Institute of Neurological Disorders and Stroke (NS017950 and UH2 NS100605). Dr. Melo van Lent received funding provided by the NIH-NIA (R03 AG067062-01), Alzheimer's Association Research Fellowship grant (AARF-22-918316) to support this research project and is supported by the NIH-NIA grants 1RF1AG059421 and 1P30 AG066546-01A1; Funds from the USDA Agricultural Research Service Agreement (No. 58-8050-9-004) supported in part the collection of dietary data for this project and the efforts of Dr. Paul Jacques. In addition, Dr. Paul Jacques is supported by R01 AG059011-01A1, R01 DK134533-01A1 and the Institute for the Advancement of Food and Nutrition Sciences; Dr. Gonzales is supported by R01 AG077472; Dr. Hugo J. Aparicio is supported by an American Academy of Neurology Career Development Award, Alzheimer's Association (AARGD-20-685362), and National Institutes of Health (L30 NS093634); Dr. Salinas is supported by R01 AG079282; Dr. Changzheng Yuan is supported by the Alzheimer's Association (AARG-22-928604) and the University Global Partnership fund; Drs. Sudha Seshadri, Jayandra J. Himali and Mitzi Gonzales are partially supported by the South Texas Alzheimer's Disease Center (1P30AG066546-01A1) and The Bill and Rebecca Reed Endowment for Precision Therapies and Palliative Care; Dr. Seshadri is also supported by 1RF1AG059421 and by an endowment from the Barker Foundation as the Robert R Barker Distinguished University Professor of Neurology, Psychiatry and Cellular and Integrative Physiology; Dr. Himali is also supported by AG062531 and by an endowment from the William Castella family as William Castella Distinguished University Chair for Alzheimer's Disease Research. The funding agencies had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board at Boston University Medical Center gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
